Casella Waste Systems, Inc. To Present at Upcoming Investor Conferences

RUTLAND, Vt., Feb. 21, 2023 (GLOBE NEWSWIRE) — Casella Waste Systems, Inc. (Nasdaq: CWST), a regional solid waste, recycling, and resource management services company, announced today that the company’s management will be participating at the following investor conferences:

  • BofA Securities 2023 Global Agriculture and Materials Conference
    Thursday, March 2, 2023
  • Raymond James 44

    th

    Annual Institutional Investors Conference
    Tuesday, March 7, 2023
  • Jefferies 2023 Business Services Summit
    Thursday, March 23, 2023

A copy of the presentation material will be available shortly before the Company presents and may be accessed via the “Events & Presentations” section of the company’s investor website at http://ir.casella.com.   In addition, a live webcast link will be posted on the company’s investor website for those conferences with presentations.

For further information, contact Jason Mead, Senior Vice President of Finance & Treasurer at (802) 772-2293, or visit the company’s website at http://www.casella.com.



Workiva Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

Workiva Inc. Announces Fourth Quarter and Full Year 2022 Financial Results

  • Increased Q4 2022 Subscription & Support Revenue by 20.7% over Q4 2021
  • Generated Total Q4 2022 Revenue of $143.8 Million, up 19.1% over Q4 2021
  • Achieved 24.2% YOY Growth of Customers with Annual Contract Value Over $150K

AMES, Iowa–(BUSINESS WIRE)–
Workiva Inc. (NYSE:WK), the company powering transparent reporting for a better world, today announced financial results for its fourth quarter and full year ended December 31, 2022.

“The Workiva team once again delivered strong financial results and outperformed against our key operating metrics. Our strong performance resulted in a 2022 revenue growth rate of 23% in Subscription & Support and 21% in total revenue,” said Marty Vanderploeg, Chief Executive Officer. “We delivered strong growth in multiple solution areas, led by ESG. ESG was one of our fastest growing solutions in 2022. This is a result of the strategic investments we made in our talent, technology, partners, and go-to-market strategy in order to capitalize on this significant market opportunity.”

“For the fourth quarter, Workiva generated record revenue, which resulted in revenue growth of 21% in Subscription & Support and 19% in total revenue,” said Jill Klindt, Chief Financial Officer. “We also delivered a Non-GAAP operating profit margin of 3.3%, beating the high end of our guidance by 660 basis points. We added 123 net new logos during the quarter, bringing our total customer count to 5,664 companies, and our gross revenue retention rate of 97.8% remains above the industry benchmark.”

“In Q4, our continued focus on driving multi-solution deals propelled our growth of large contract values,” added Vanderploeg. “Workiva offers the only assured integrated reporting platform that brings Financial Reporting, ESG, and GRC together in one controlled, secure, audit-ready environment. This unified platform offering is a unique and key differentiator that provides our customers with the best, most complete business reporting capabilities on the market.”

Fourth Quarter 2022 Financial Highlights

  • Revenue: Total revenue for the fourth quarter of 2022 reached$143.8 million, an increase of 19.1% from $120.8 million in the fourth quarter of 2021. Subscription and support revenue contributed $125.9 million, up 20.7% versus the fourth quarter of 2021. Professional services revenue was $17.9 million, an increase of 8.7% compared to the same quarter in the prior year.
  • Gross Profit: GAAP gross profit for the fourth quarter of 2022 was $109.4 million compared with $91.6 million in the same quarter of 2021. GAAP gross margin was 76.1% versus 75.9% in the fourth quarter of 2021. Non-GAAP gross profit for the fourth quarter of 2022 was $110.9 million, an increase of 19.0% compared with the prior year’s fourth quarter, and non-GAAP gross margin was 77.1% compared to 77.2% in the fourth quarter of 2021.
  • Results from Operations: GAAP loss from operations for the fourth quarter of 2022 was $13.3 million compared with a loss of $11.5 million in the prior year’s fourth quarter. Non-GAAP income from operations was $4.8 million, compared with non-GAAP income from operations of $2.2 million in the fourth quarter of 2021.
  • GAAP Net Loss: GAAP net loss for the fourth quarter of 2022 was $13.9 million compared with a net loss of $14.3 million for the prior year’s fourth quarter. GAAP net loss per basic and diluted share was $0.26 compared with a net loss per basic and diluted share of $0.28 in the fourth quarter of 2021.
  • Non-GAAP Net Income: Non-GAAP net income for the fourth quarter of 2022 was $4.2 million compared with net income of $1.7 million in the prior year’s fourth quarter. Non-GAAP net income per basic share and diluted share was $0.08, compared with net income per basic share and diluted share of $0.03 in the fourth quarter of 2021.
  • Liquidity: As of December 31, 2022, Workiva had cash, cash equivalents, and marketable securities totaling $430.8 million, compared with $530.4 million as of December 31, 2021. Workiva had $345.0 million aggregate principal amount of 1.125% convertible senior notes due in 2026 and $15.1 million of finance lease obligations outstanding as of December 31, 2022.

Key Metrics and Recent Business Highlights

  • Customers: Workiva had 5,664 customers as of December 31, 2022, including approximately 922 ParsePort ESEF customers, a net increase of 1,349 customers from December 31, 2021.
  • Revenue Retention Rate: As of December 31, 2022, Workiva’s revenue retention rate (excluding add-on revenue) was 97.8%, and the revenue retention rate including add-on revenue was 108.5%. Add-on revenue includes changes in both solutions and pricing for existing customers.
  • Large Contracts: As of December 31, 2022, Workiva had 1,345 customers with an annual contract value (“ACV”) of more than $100,000, up 20% from 1,121 customers at December 31, 2021. Workiva had 718 customers with an ACV of more than $150,000, up 24% from 578 customers in the fourth quarter of 2021. Workiva had 236 customers with an ACV of more than $300,000, up 29% from 183 customers in the fourth quarter of 2021.

Full Year 2022 Financial Highlights

  • Revenue: Total revenue for the full year 2022 reached $537.9 million, an increase of 21.3% from $443.3 million in 2021. Subscription and support revenue contributed $464.9 million, up 22.6% compared to 2021. Professional services revenue was $72.9 million, an increase of 14.1% compared to the prior year.
  • Gross Profit: GAAP gross profit for 2022 was $408.0 million compared with $339.5 million in 2021. GAAP gross margin was 75.9% versus 76.6% in the prior year. Non-GAAP gross profit for 2022 was $413.6 million, an increase of 20.2% compared to 2021, and non-GAAP gross margin was 76.9% compared to 77.6%.
  • Results from Operations: GAAP loss from operations for 2022 was $88.8 million compared with a loss of $29.4 million in the prior year. Non-GAAP loss from operations was $13.0 million, compared with non-GAAP income from operations of $20.0 million in 2021.
  • GAAP Net Loss: GAAP net loss for 2022 was $90.9 million compared with a net loss of $37.7 million in the prior year. GAAP net loss per basic and diluted share was $1.72 compared with a net loss per basic and diluted share of $0.74 in 2021.
  • Non-GAAP Net Loss/Income: Non-GAAP net loss for 2022 was $15.2 million compared with net income of $20.8 million in the prior year. Non-GAAP net loss per basic and diluted share was $0.29, compared with net income per basic share and diluted share of $0.41 and $0.37, respectively, in 2021.
  • Cash Flow: Net cash provided by operating activities was $11.3 million in 2022, compared to cash provided by operating activities of $49.8 million in 2021.

Financial Outlook

As of February 21, 2023, Workiva is providing guidance as follows:

First Quarter 2023 Guidance:

  • Total revenue is expected to be in the range of $149.0 million to $150.0 million.
  • GAAP loss from operations is expected to be in the range of $52.0 million to $51.0 million.
  • Non-GAAP loss from operations is expected to be in the range of $12.0 million to $11.0 million.
  • GAAP net loss per basic share is expected to be in the range of $0.97 to $0.95.
  • Non-GAAP net loss per basic share is expected to be in the range of $0.23 to $0.21.
  • Net loss per basic share is based on 53.7 million weighted-average shares outstanding.

Full Year 2023 Guidance:

  • Total revenue is expected to be in the range of $624.0 million to $626.0 million.
  • GAAP loss from operations is expected to be in the range of $111.0 million to $109.0 million.
  • Non-GAAP loss from operations is expected to be in the range of $9.0 million to $7.0 million.
  • GAAP net loss per basic share is expected to be in the range of $2.02 to $1.99.
  • Non-GAAP net loss per basic share is expected to be in the range of $0.13 to $0.10.
  • Net loss per basic share is based on 54.0 million weighted-average shares outstanding.

Quarterly Conference Call

Workiva will host a conference call today at 5:00 p.m. ET to review the Company’s financial results for the fourth quarter and full year 2022, in addition to discussing the Company’s outlook for the first quarter and full year 2023. To access this call, dial 888-330-2469 (U.S. domestic) or 240-789-2740 (international). The conference ID is 8736384. A live webcast of the conference call will be accessible in the “Investor Relations” section of Workiva’s website at www.workiva.com. A replay of this conference call can also be accessed through February 28, 2023, at 800-770-2030 (U.S. domestic) or 647-362-9199 (international). The replay pass code is 8736384. An archived webcast of this conference call will also be available an hour after the completion of the call in the “Investor Relations” section of the Company’s website at www.workiva.com.

About Workiva

Workiva Inc. (NYSE:WK) is on a mission to power transparent reporting for a better world. We build and deliver the world’s leading cloud platform for assured integrated reporting to meet stakeholder demands for action, transparency, and disclosure of financial and non-financial data. Workiva offers the only unified SaaS platform that brings customers’ financial reporting, Environmental, Social, and Governance (ESG), and Governance, Risk, and Compliance (GRC) together in a controlled, secure, audit-ready platform. Our platform simplifies the most complex reporting and disclosure challenges by streamlining processes, connecting data and teams, and ensuring consistency. Learn more at workiva.com.

Follow Workiva on LinkedIn: www.linkedin.com/company/workiva

Like Workiva on Facebook: www.facebook.com/workiva

Follow Workiva on Twitter: www.twitter.com/workiva

Non-GAAP Financial Measures

The non-GAAP adjustments referenced herein relate to the exclusion of stock-based compensation, amortization of acquisition-related intangible assets and non-cash interest expense related to our convertible senior notes. A reconciliation of GAAP to non-GAAP historical financial measures has been provided in Table I at the end of this press release. A reconciliation of GAAP to non-GAAP guidance has been provided in Table II at the end of this press release.

Workiva believes that the use of non-GAAP gross profit and gross margin, non-GAAP income (loss) from operations, non-GAAP net income (loss) and non-GAAP net income (loss) per share is helpful to its investors. These measures, which are referred to as non-GAAP financial measures, are not prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Non-GAAP gross profit is calculated by excluding stock-based compensation expense attributable to cost of revenues from gross profit. Non-GAAP gross margin is the ratio calculated by dividing non-GAAP gross profit by revenues. Non-GAAP income (loss) from operations is calculated by excluding stock-based compensation expense and amortization expense for acquisition-related intangible assets from loss from operations. Non-GAAP net income (loss) is calculated by excluding stock-based compensation expense, net of tax, amortization expense for acquisition-related intangible assets, and non-cash interest expense related to our convertible senior notes from net loss. Non-GAAP net income (loss) per share is calculated by dividing non-GAAP net income (loss) by the weighted- average shares outstanding as presented in the calculation of GAAP net loss per share. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Workiva believes that providing non-GAAP financial measures that exclude stock-based compensation expense allows for more meaningful comparisons between its operating results from period to period. For business combinations, we generally allocate a portion of the purchase price to intangible assets. The amount of the allocation is based on estimates and assumptions made by management and is subject to amortization. The amount of purchase price allocated to intangible assets and the term of its related amortization can vary significantly and are unique to each acquisition and thus we do not believe it is reflective of ongoing operations. Under GAAP, certain convertible debt instruments that may be settled in cash on conversion are required to be accounted for as separate liability and equity components in a manner that reflects our non-convertible debt borrowing rate. This results in the debt component being treated as though it was issued at a discount, with the debt discount being accreted as additional non-cash interest expense over the term of the notes using the effective interest method. As a result, we believe that excluding this non-cash interest expense attributable to the debt discount in calculating our non-GAAP measures is useful because this interest expense does not represent a cash outflow and is not indicative of our ongoing operational performance. Workiva’s management uses these non-GAAP financial measures as tools for financial and operational decision making and for evaluating Workiva’s own operating results over different periods of time.

Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in Workiva’s industry, as other companies in the industry may calculate non-GAAP financial results differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Workiva’s reported financial results. Further, stock-based compensation expense has been and will continue to be for the foreseeable future a significant recurring expense in Workiva’s business and an important part of the compensation provided to its employees. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Investors should review the reconciliation of non-GAAP financial measures to the comparable GAAP financial measures included below, and not rely on any single financial measure to evaluate Workiva’s business.

Safe Harbor Statement

Certain statements in this press release are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the Company’s expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “outlook,” “guidance” or the negative of those terms or other comparable terminology.

Please see the Company’s documents filed or to be filed with the Securities and Exchange Commission, including the Company’s annual reports filed on Form 10-K and quarterly reports on Form 10-Q, and any amendments thereto for a discussion of certain important risk factors that relate to forward-looking statements contained in this report. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Any forward-looking statements are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

WORKIVA INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

 

 

Three months ended

December 31,

 

Year ended December 31,

 

2022

 

2021

 

2022

 

2021

 

(unaudited)

 

 

 

 

Revenue

 

 

 

 

 

 

 

Subscription and support

$

125,871

 

 

$

104,287

 

 

$

464,935

 

 

$

379,340

 

Professional services

 

17,932

 

 

 

16,496

 

 

 

72,940

 

 

 

63,945

 

Total revenue

 

143,803

 

 

 

120,783

 

 

 

537,875

 

 

 

443,285

 

Cost of revenue

 

 

 

 

 

 

 

Subscription and support (1)

 

21,028

 

 

 

17,645

 

 

 

77,711

 

 

 

60,551

 

Professional services (1)

 

13,328

 

 

 

11,516

 

 

 

52,174

 

 

 

43,282

 

Total cost of revenue

 

34,356

 

 

 

29,161

 

 

 

129,885

 

 

 

103,833

 

Gross profit

 

109,447

 

 

 

91,622

 

 

 

407,990

 

 

 

339,452

 

Operating expenses

 

 

 

 

 

 

 

Research and development (1)

 

38,072

 

 

 

31,430

 

 

 

151,716

 

 

 

115,735

 

Sales and marketing (1)

 

60,381

 

 

 

50,199

 

 

 

245,260

 

 

 

178,785

 

General and administrative (1)

 

24,271

 

 

 

21,492

 

 

 

99,778

 

 

 

74,287

 

Total operating expenses

 

122,724

 

 

 

103,121

 

 

 

496,754

 

 

 

368,807

 

Loss from operations

 

(13,277

)

 

 

(11,499

)

 

 

(88,764

)

 

 

(29,355

)

Interest income

 

2,555

 

 

 

207

 

 

 

4,880

 

 

 

1,041

 

Interest expense

 

(1,502

)

 

 

(3,520

)

 

 

(6,042

)

 

 

(14,015

)

Other (expense) and income, net

 

(541

)

 

 

(36

)

 

 

926

 

 

 

3,229

 

Loss before provision (benefit) for income taxes

 

(12,765

)

 

 

(14,848

)

 

 

(89,000

)

 

 

(39,100

)

Provision (benefit) for income taxes

 

1,137

 

 

 

(524

)

 

 

1,947

 

 

 

(1,370

)

Net loss

$

(13,902

)

 

$

(14,324

)

 

$

(90,947

)

 

$

(37,730

)

Net loss per common share:

 

 

 

 

 

 

 

Basic and diluted

$

(0.26

)

 

$

(0.28

)

 

$

(1.72

)

 

$

(0.74

)

Weighted-average common shares outstanding – basic and diluted

 

53,279,147

 

 

 

51,734,522

 

 

 

52,954,079

 

 

 

51,126,510

 

 

(1) Includes stock-based compensation expense as follows:

 

Three months ended

December 31,

 

Year ended December 31,

 

2022

 

2021

 

2022

 

2021

 

(unaudited)

 

 

 

 

Cost of revenue

 

 

 

 

 

 

 

Subscription and support

$

880

 

$

1,044

 

$

3,437

 

$

2,868

Professional services

 

550

 

 

546

 

 

2,128

 

 

1,729

Operating expenses

 

 

 

 

 

 

 

Research and development

 

3,282

 

 

2,395

 

 

12,554

 

 

9,590

Sales and marketing

 

4,935

 

 

3,420

 

 

19,323

 

 

13,901

General and administrative

 

6,960

 

 

5,866

 

 

33,218

 

 

20,545

WORKIVA INC.

 

CONSOLIDATED BALANCE SHEETS

(in thousands)

 

 

As of December 31,

 

2022

 

2021

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

240,197

 

 

$

300,386

 

Marketable securities

 

190,595

 

 

 

230,060

 

Accounts receivable, net

 

106,316

 

 

 

76,848

 

Deferred costs

 

38,350

 

 

 

31,152

 

Other receivables

 

6,674

 

 

 

3,538

 

Prepaid expenses and other

 

17,957

 

 

 

15,108

 

Total current assets

 

600,089

 

 

 

657,092

 

Property and equipment, net

 

27,096

 

 

 

28,821

 

Operating lease right-of-use assets

 

13,932

 

 

 

17,760

 

Deferred costs, non-current

 

33,682

 

 

 

33,091

 

Goodwill

 

109,740

 

 

 

34,556

 

Intangible assets, net

 

28,234

 

 

 

10,434

 

Other assets

 

6,847

 

 

 

5,005

 

Total assets

$

819,620

 

 

$

786,759

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities

 

 

 

Accounts payable

$

6,174

 

 

$

4,114

 

Accrued expenses and other current liabilities

 

83,999

 

 

 

84,126

 

Deferred revenue

 

316,263

 

 

 

258,023

 

Convertible senior notes, current

 

 

 

 

298,661

 

Finance lease obligations

 

504

 

 

 

1,575

 

Total current liabilities

 

406,940

 

 

 

646,499

 

Convertible senior notes, non-current

 

340,257

 

 

 

 

Deferred revenue, non-current

 

38,237

 

 

 

34,181

 

Other long-term liabilities

 

1,518

 

 

 

1,605

 

Operating lease liabilities, non-current

 

12,102

 

 

 

16,408

 

Finance lease obligations, non-current

 

14,583

 

 

 

15,087

 

Total liabilities

 

813,637

 

 

 

713,780

 

Stockholders’ equity

 

 

 

Common stock

 

53

 

 

 

51

 

Additional paid-in-capital

 

537,732

 

 

 

525,646

 

Accumulated deficit

 

(525,116

)

 

 

(452,430

)

Accumulated other comprehensive loss

 

(6,686

)

 

 

(288

)

Total stockholders’ equity

 

5,983

 

 

 

72,979

 

Total liabilities and stockholders’ equity

$

819,620

 

 

$

786,759

 

WORKIVA INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

Three months ended

December 31,

 

Year ended December 31,

 

2022

 

2021

 

2022

 

2021

 

(unaudited)

 

 

 

 

Cash flows from operating activities

 

 

 

 

 

 

 

Net loss

$

(13,902

)

 

$

(14,324

)

 

$

(90,947

)

 

$

(37,730

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

2,847

 

 

 

1,664

 

 

 

10,212

 

 

 

5,244

 

Stock-based compensation expense

 

16,607

 

 

 

13,271

 

 

 

70,660

 

 

 

48,633

 

Provision for (recovery of) doubtful accounts

 

74

 

 

 

37

 

 

 

156

 

 

 

(125

)

(Accretion) amortization of premiums and discounts on marketable securities, net

 

(163

)

 

 

825

 

 

 

1,079

 

 

 

3,024

 

Gain on settlement of equity securities

 

 

 

 

 

 

 

 

 

 

(3,698

)

Amortization of issuance costs and debt discount

 

325

 

 

 

2,320

 

 

 

1,298

 

 

 

9,171

 

Deferred income tax

 

629

 

 

 

(1,059

)

 

 

538

 

 

 

(1,973

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

(22,703

)

 

 

(12,916

)

 

 

(28,893

)

 

 

(7,683

)

Deferred costs

 

(5,834

)

 

 

(7,103

)

 

 

(8,496

)

 

 

(19,207

)

Operating lease right-of-use asset

 

1,276

 

 

 

1,291

 

 

 

5,153

 

 

 

4,197

 

Other receivables

 

(1,693

)

 

 

(187

)

 

 

(1,655

)

 

 

(391

)

Prepaid expenses

 

(3,783

)

 

 

(2,473

)

 

 

(2,913

)

 

 

(6,522

)

Other assets

 

(1,336

)

 

 

(25

)

 

 

(2,441

)

 

 

(1,222

)

Accounts payable

 

(3,557

)

 

 

(242

)

 

 

2,438

 

 

 

972

 

Deferred revenue

 

33,084

 

 

 

25,391

 

 

 

61,657

 

 

 

47,419

 

Operating lease liability

 

(1,298

)

 

 

(1,544

)

 

 

(5,055

)

 

 

(4,934

)

Accrued expenses and other liabilities

 

(1,841

)

 

 

4,342

 

 

 

(1,457

)

 

 

14,669

 

Net cash (used in) provided by operating activities

 

(1,268

)

 

 

9,268

 

 

 

11,334

 

 

 

49,844

 

Cash flows from investing activities

 

 

 

 

 

 

 

Purchase of property and equipment

 

(1,232

)

 

 

(1,103

)

 

 

(3,458

)

 

 

(3,534

)

Purchase of marketable securities

 

(31,190

)

 

 

(26,985

)

 

 

(130,754

)

 

 

(170,070

)

Sale of marketable securities

 

 

 

 

 

 

 

14,981

 

 

 

250

 

Maturities of marketable securities

 

43,708

 

 

 

26,788

 

 

 

150,565

 

 

 

143,159

 

Acquisitions, net of cash acquired

 

 

 

 

(2,400

)

 

 

(99,186

)

 

 

(37,467

)

Purchase of intangible assets

 

(52

)

 

 

(32

)

 

 

(160

)

 

 

(219

)

Other investments

 

 

 

 

 

 

 

 

 

 

(750

)

Net cash provided by (used in) investing activities

 

11,234

 

 

 

(3,732

)

 

 

(68,012

)

 

 

(68,631

)

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

Proceeds from option exercises

 

678

 

 

 

7,808

 

 

 

3,273

 

 

 

16,600

 

Taxes paid related to net share settlements of stock-based compensation awards

 

(1,889

)

 

 

(3,458

)

 

 

(12,541

)

 

 

(27,144

)

Proceeds from shares issued in connection with employee stock purchase plan

 

 

 

 

 

 

 

9,256

 

 

 

8,861

 

Principal payments on finance lease obligations

 

(233

)

 

 

(434

)

 

 

(1,575

)

 

 

(1,705

)

Net cash (used in) provided by financing activities

 

(1,444

)

 

 

3,916

 

 

 

(1,587

)

 

 

(3,388

)

Effect of foreign exchange rates on cash

 

2,178

 

 

 

(191

)

 

 

(1,924

)

 

 

(270

)

Net increase (decrease) in cash and cash equivalents

 

10,700

 

 

 

9,261

 

 

 

(60,189

)

 

 

(22,445

)

Cash and cash equivalents at beginning of period

 

229,497

 

 

 

291,125

 

 

 

300,386

 

 

 

322,831

 

Cash and cash equivalents at end of period

$

240,197

 

 

$

300,386

 

 

$

240,197

 

 

$

300,386

 

TABLE I

WORKIVA INC.

RECONCILIATION OF NON-GAAP INFORMATION

(in thousands, except share and per share)

 

 

Three months ended

December 31,

 

Year ended December 31,

 

2022

 

2021

 

2022

 

2021

Gross profit, subscription and support

$

104,843

 

 

$

86,642

 

 

$

387,224

 

 

$

318,789

 

Add back: Stock-based compensation

 

880

 

 

 

1,044

 

 

 

3,437

 

 

 

2,868

 

Gross profit, subscription and support, non-GAAP

$

105,723

 

 

$

87,686

 

 

$

390,661

 

 

$

321,657

 

 

 

 

 

 

 

 

 

Gross profit, professional services

$

4,604

 

 

$

4,980

 

 

$

20,766

 

 

$

20,663

 

Add back: Stock-based compensation

 

550

 

 

 

546

 

 

 

2,128

 

 

 

1,729

 

Gross profit, professional services, non-GAAP

$

5,154

 

 

$

5,526

 

 

$

22,894

 

 

$

22,392

 

 

 

 

 

 

 

 

 

Gross profit

$

109,447

 

 

$

91,622

 

 

$

407,990

 

 

$

339,452

 

Add back: Stock-based compensation

 

1,430

 

 

 

1,590

 

 

 

5,565

 

 

 

4,597

 

Gross profit, non-GAAP

$

110,877

 

 

$

93,212

 

 

$

413,555

 

 

$

344,049

 

 

 

 

 

 

 

 

 

Cost of revenue, subscription and support

$

21,028

 

 

$

17,645

 

 

$

77,711

 

 

$

60,551

 

Less: Stock-based compensation

 

880

 

 

 

1,044

 

 

 

3,437

 

 

 

2,868

 

Cost of revenue, subscription and support, non-GAAP

$

20,148

 

 

$

16,601

 

 

$

74,274

 

 

$

57,683

 

 

 

 

 

 

 

 

 

Cost of revenue, professional services

$

13,328

 

 

$

11,516

 

 

$

52,174

 

 

$

43,282

 

Less: Stock-based compensation

 

550

 

 

 

546

 

 

 

2,128

 

 

 

1,729

 

Cost of revenue, professional services, non-GAAP

$

12,778

 

 

$

10,970

 

 

$

50,046

 

 

$

41,553

 

 

 

 

 

 

 

 

 

Research and development

$

38,072

 

 

$

31,430

 

 

$

151,716

 

 

$

115,735

 

Less: Stock-based compensation

 

3,282

 

 

 

2,395

 

 

 

12,554

 

 

 

9,590

 

Less: Amortization of acquisition-related intangibles

 

867

 

 

 

426

 

 

 

3,107

 

 

 

701

 

Research and development, non-GAAP

$

33,923

 

 

$

28,609

 

 

$

136,055

 

 

$

105,444

 

 

 

 

 

 

 

 

 

Sales and marketing

$

60,381

 

 

$

50,199

 

 

$

245,260

 

 

$

178,785

 

Less: Stock-based compensation

 

4,935

 

 

 

3,420

 

 

 

19,323

 

 

 

13,901

 

Less: Amortization of acquisition-related intangibles

 

581

 

 

 

22

 

 

 

1,954

 

 

 

35

 

Sales and marketing, non-GAAP

$

54,865

 

 

$

46,757

 

 

$

223,983

 

 

$

164,849

 

 

 

 

 

 

 

 

 

General and administrative

$

24,271

 

 

$

21,492

 

 

$

99,778

 

 

$

74,287

 

Less: Stock-based compensation

 

6,960

 

 

 

5,866

 

 

 

33,218

 

 

 

20,545

 

General and administrative, non-GAAP

$

17,311

 

 

$

15,626

 

 

$

66,560

 

 

$

53,742

 

 

 

 

 

 

 

 

 

Loss from operations

$

(13,277

)

 

$

(11,499

)

 

$

(88,764

)

 

$

(29,355

)

Add back: Stock-based compensation

 

16,607

 

 

 

13,271

 

 

 

70,660

 

 

 

48,633

 

Add back: Amortization of acquisition-related intangibles

 

1,448

 

 

 

448

 

 

 

5,061

 

 

 

736

 

Income (loss) from operations, non-GAAP

$

4,778

 

 

$

2,220

 

 

$

(13,043

)

 

$

20,014

 

 

 

 

 

 

 

 

 

Net loss

$

(13,902

)

 

$

(14,324

)

 

$

(90,947

)

 

$

(37,730

)

Add back: Stock-based compensation

 

16,607

 

 

 

13,271

 

 

 

70,660

 

 

 

48,633

 

Add back: Amortization of acquisition-related intangibles

 

1,448

 

 

 

448

 

 

 

5,061

 

 

 

736

 

Add back: Non-cash interest expense related to convertible senior notes

 

 

 

 

2,320

 

 

 

 

 

 

9,171

 

Net income (loss), non-GAAP

$

4,153

 

 

$

1,715

 

 

$

(15,226

)

 

$

20,810

 

 

 

 

 

 

 

 

 

Net loss per basic and diluted share:

$

(0.26

)

 

$

(0.28

)

 

$

(1.72

)

 

$

(0.74

)

Add back: Stock-based compensation

 

0.31

 

 

 

0.26

 

 

 

1.33

 

 

 

0.96

 

Add back: Amortization of acquisition-related intangibles

 

0.03

 

 

 

0.01

 

 

 

0.10

 

 

 

0.01

 

Add back: Non-cash interest expense related to convertible senior notes

 

 

 

 

0.04

 

 

 

 

 

 

0.18

 

Net income (loss) per basic share, non-GAAP

$

0.08

 

 

$

0.03

 

 

$

(0.29

)

 

$

0.41

 

Net income (loss) per diluted share, non-GAAP

$

0.08

 

 

$

0.03

 

 

$

(0.29

)

 

$

0.37

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding – basic, non-GAAP

 

53,279,147

 

 

 

51,734,522

 

 

 

52,954,079

 

 

 

51,126,510

 

Weighted-average common shares outstanding – diluted, non-GAAP

 

54,938,441

 

 

 

56,697,006

 

 

 

52,954,079

 

 

 

55,998,736

 

TABLE II

WORKIVA INC.

RECONCILIATION OF NON-GAAP GUIDANCE

(in thousands, except share and per share data)

 

Three months ending March 31,

2023

 

Year ending December 31, 2023

 

 

 

 

 

 

 

 

Loss from operations, GAAP range

$

(52,000

)

$

(51,000

)

 

$

(111,000

)

$

(109,000

)

Add back: Stock-based compensation

 

38,528

 

 

 

38,528

 

 

 

96,158

 

 

 

96,158

 

Add back: Amortization of acquisition-related intangibles

 

1,472

 

 

 

1,472

 

 

 

5,842

 

 

 

5,842

 

Net loss from operations, non-GAAP range

$

(12,000

)

$

(11,000

)

 

$

(9,000

)

$

(7,000

)

 

 

 

 

 

 

 

 

Net loss per share, GAAP range

$

(0.97

)

$

(0.95

)

 

$

(2.02

)

$

(1.99

)

Add back: Stock-based compensation

 

0.72

 

 

 

0.72

 

 

 

1.78

 

 

 

1.78

 

Add back: Amortization of acquisition-related intangibles

 

0.03

 

 

 

0.03

 

 

 

0.11

 

 

 

0.11

 

Net loss per share, non-GAAP range

$

(0.23

)

$

(0.21

)

 

$

(0.13

)

$

(0.10

)

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding – basic

 

53,700,000

 

 

 

53,700,000

 

 

 

54,000,000

 

 

 

54,000,000

 

 

Investor Contact:

Mike Rost

Workiva Inc.

[email protected]

(515) 663-4493

Media Contact:

Darcie Brossart

Workiva Inc.

[email protected]

(515) 663-4471

KEYWORDS: United States North America Iowa

INDUSTRY KEYWORDS: Finance Public Relations/Investor Relations Communications Professional Services Other Communications

MEDIA:

Logo
Logo

EPR Properties Elects John Case as New Board Member

EPR Properties Elects John Case as New Board Member

KANSAS CITY, Mo.–(BUSINESS WIRE)–
EPR Properties (NYSE: EPR) today announced that John P. Case III has been elected to its Board of Trustees.

Mr. Case has been a Partner and Senior Advisor for the Ares Net Lease strategy on a part time basis since 2021. Prior to joining Ares, Mr. Case was CEO, President and Director of Realty Income Corporation. Additionally, Mr. Case served on the Board of Directors of Duke Realty Corporation before it was acquired by Prologis, Inc. Mr. Case also served as Chief Investment Officer and chaired the Investment Committee of Realty Income. He has served on the Executive Board of the National Association of Real Estate Investment Trusts as well as on The Real Estate Roundtable. Prior to joining Realty Income, Mr. Case served for 19 years as a New York-based real estate investment banker, where he was responsible for more than $100 billion in real estate capital markets and advisory transactions.

“John brings deep management, financial and REIT expertise to our Board, particularly his experience leading Realty Income, the largest public net lease REIT,” said Greg Silvers, Chairman and CEO of EPR Properties. “We are excited to add John to our Board and look forward to tapping into his experience and perspectives as we continue building the leading diversified experiential REIT.”

The election of Mr. Case is in anticipation of Jack Newman’s retirement from the Board at this year’s annual meeting of shareholders in accordance with the Company’s trustee age limit policy under its Company Governance Guidelines.

“The Company is grateful for the years of dedicated service provided by Jack,” said Mr. Silvers, “Jack has provided a diligent and independent voice in board meetings that has contributed to our ongoing success. As chair of our Audit Committee, his leadership has ensured that our reporting and accounting practices have been conducted at the highest professional and ethical manner.”

About EPR Properties

EPR Properties (NYSE:EPR) is the leading diversified experiential net lease real estate investment trust (REIT), specializing in select enduring experiential properties in the real estate industry. We focus on real estate venues which create value by facilitating out of home leisure and recreation experiences where consumers choose to spend their discretionary time and money. We have total assets of approximately $5.8 billion (after accumulated depreciation of approximately $1.3 billion) across 44 states. We adhere to rigorous underwriting and investing criteria centered on key industry, property and tenant level cash flow standards. We believe our focused approach provides a competitive advantage and the potential for stable and attractive returns. Further information is available at www.eprkc.com.

EPR Properties

Brian Moriarty

Vice President, Corporate Communications

[email protected] | 816-472-1700

KEYWORDS: United States North America Missouri

INDUSTRY KEYWORDS: Entertainment General Entertainment Commercial Building & Real Estate Construction & Property Destinations Travel REIT

MEDIA:

Ingevity elects new member to its Board of Directors

Ingevity elects new member to its Board of Directors

NORTH CHARLESTON, S.C.–(BUSINESS WIRE)–
Ingevity Corporation (NYSE:NGVT) today announced the election of Bruce Hoechner to the board of directors effective February 16, 2023. He joins nine other members of Ingevity’s board of directors.

Mr.Hoechnerserved as president and chief executive officer of Rogers Corporation, an innovator and producer of specialty materials and components for applications in the communications, personal electronics, advanced transportation, consumer and industrial markets, from 2011 until his retirement in 2022. He previously served as president, Asia Pacific region, based in Shanghai, China, for Dow Chemical Company from 2009 to 2011. Prior to its acquisition by Dow Chemical Company, Mr. Hoechner held positions of increasing responsibility in the U.S. and internationally with the Rohm and Haas Company.

“We are pleased to welcome this talented and experienced leader to the Board of Directors,” said Jean Blackwell, chair of Ingevity’s board. “His global leadership experience and expertise in international marketing and business strategy development will bring valuable insights that can help accelerate Ingevity’s growth and amplify our sustainability efforts.”

Ingevity: Purify, Protect and Enhance

Ingevity provides products and technologies that purify, protect and enhance the world around us. Through a team of talented and experienced people, we develop, manufacture and bring to market solutions that help customers solve complex problems and make the world more sustainable. We operate in two reporting segments: Performance Chemicals, which includes specialty chemicals and engineered polymers, and Performance Materials, which includes high-performance activated carbon. These products are used in a variety of demanding applications, including adhesives, agrochemicals, asphalt paving, bioplastics, coatings, elastomers, lubricants, pavement markings, publication inks, oil exploration and production and automotive components that reduce gasoline vapor emissions. Headquartered in North Charleston, South Carolina, Ingevity operates from 31 locations around the world and employs approximately 2,050 people. The company’s common stock is traded on the New York Stock Exchange (NYSE:NGVT). For more information visit www.ingevity.com. Follow Ingevity on LinkedIn.

Caroline Monahan

843-740-2068

[email protected]

Investors:

John Nypaver

843-740-2002

[email protected]

KEYWORDS: United States North America South Carolina

INDUSTRY KEYWORDS: Chemicals/Plastics Manufacturing

MEDIA:

Logo
Logo

Ooma to Attend the William Blair 7th Annual Tech Innovators Conference

Ooma to Attend the William Blair 7th Annual Tech Innovators Conference

SUNNYVALE, Calif.–(BUSINESS WIRE)–
Ooma, Inc. (NYSE: OOMA), a smart communications platform for businesses and consumers, today announced the following conference participation:

What: William Blair 7th Annual Tech Innovators Conference of virtual 1-on-1 meetings (no public presentation or webcast)

When: March 15, 2023, with meetings throughout the day

Who: Ooma CEO Eric Stang and Ooma CFO Shig Hamamatsu

Where: Virtual

Interested parties should contact their William Blair & Company sales representative for further details and meeting opportunities.

About Ooma, Inc.

Ooma (NYSE: OOMA) creates powerful connected experiences for businesses and consumers, delivered from its smart cloud-based SaaS platform. For businesses of all sizes, Ooma provides advanced voice and collaboration features including messaging, intelligent virtual attendants and videoconferencing to help them run more efficiently. For consumers, Ooma’s residential phone service provides PureVoice HD voice quality, advanced functionality and integration with mobile devices. Learn more at www.ooma.com or www.ooma.ca in Canada.

INVESTOR CONTACT:

Matthew S. Robison

Director of IR and Corporate Development

Ooma, Inc.

[email protected]

(650) 300-1480

MEDIA CONTACT:

Mike Langberg

Director of Corporate Communications

Ooma, Inc.

[email protected]

(650) 566-6693

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Logo
Logo

Citi CFO Mark Mason to Present at the 2023 RBC Capital Markets Financial Institutions Conference

Citi CFO Mark Mason to Present at the 2023 RBC Capital Markets Financial Institutions Conference

NEW YORK–(BUSINESS WIRE)–
Mark Mason, Chief Financial Officer of Citi, will present at the 2023 RBC Capital Markets Financial Institutions Conference on Wednesday, March 8. The presentation is expected to begin at approximately 3:20 p.m. (Eastern). A live webcast will be available at http://www.citigroup.com/citi/investor. A replay and transcript of the webcast will be available shortly after the event.

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in nearly 160 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi| Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn:www.linkedin.com/company/citi

Media: Danielle Romero-Apsilos (212) 816-2264

Investors: Jennifer Landis (212) 559-2718

Fixed Income Investors: Peter Demoise (212) 559-2718

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

  • SYFOVRE™ (pegcetacoplan injection) approved in the U.S. as the first and only treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
  • EU marketing authorization application for intravitreal pegcetacoplan validated by the European Medicines Agency; decision by European Commission (EC) expected in early 2024
  • EMPAVELI

    ®

    (pegcetacoplan) sNDA approved including Phase 3 PRINCE data and 48-week Phase 3 PEGASUS data
  • Generated $65.1 million in full year 2022 EMPAVELI U.S. net product revenues

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights.

“2022 was another year of remarkable execution for Apellis as we moved closer toward our goal of bringing SYFOVRE to patients with GA worldwide and continued to elevate the standard of care in PNH with EMPAVELI. Last week, we were thrilled to announce the FDA approval of SYFOVRE as the first and only treatment approved for patients living with GA, and we are now ready to launch in the U.S.,” said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis. “With two commercial products, a robust pipeline of multiple late-stage programs, and a portfolio of pre-clinical assets heading towards the clinic, we believe we are in a strong position for 2023 and beyond.”

Dr. Francois continued, “With our first two approvals in less than two years, we believe we have only begun to unlock the potential of targeting C3 to treat some of the most challenging diseases that patients face. We look forward to building on this momentum.”

Fourth Quarter and Full Year 2022 Business Highlights and Upcoming Milestones:


Ophthalmology Highlights

  • SYFOVRE for the treatment of GA secondary to AMD:

    • On February 17, 2023, the FDA approved SYFOVRE for the treatment of GA secondary to AMD. Apellis expects the commercial launch of SYFOVRE by the beginning of March 2023.
    • A marketing authorization application for intravitreal pegcetacoplan was validated and is currently under review by the European Medicines Agency with an EC decision expected in early 2024.
    • Apellis also submitted a New Drug Submission for SYFOVRE to Health Canada and expects to submit applications in Switzerland, Australia and the United Kingdom in the first quarter of 2023.
  • APL-2006: Apellis expects to submit an investigational new drug (IND) application for APL-2006, a bispecific C3 and VEGF inhibitor, in the first half of 2023.


Paroxysmal Nocturnal Hemoglobinuria (PNH) Highlights

  • EMPAVELI for the treatment of PNH:

    • Apellis recorded $19.7 million and $65.1 million in EMPAVELI U.S. net product revenue for the fourth quarter and full year 2022, respectively.
    • In February 2023, the FDA approved the supplemental new drug application (sNDA) with the Phase 3 PRINCE results and the 48-week Phase 3 PEGASUS data.
    • The Prescription Drug User Fee Act (PDUFA) target action date for the EMPAVELI Injector sNDA is March 15, 2023. EMPAVELI injector is a custom, on-body drug delivery system that would enable patients to self-administer pegcetacoplan through subcutaneous infusion.


Rare Disease R&D Highlights

  • Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G): Apellis continues to enroll patients in the Phase 3 VALIANT study of systemic pegcetacoplan for IC-MPGN and C3G.
  • Amyotrophic lateral sclerosis (ALS): Apellis expects to report top-line results from its ongoing and potentially registrational Phase 2 MERIDIAN study of systemic pegcetacoplan for ALS in mid-2023.
  • Cold agglutinin disease (CAD): Sobi, Apellis’ global co-development partner for systemic pegcetacoplan, continues to enroll patients in the Phase 3 CASCADE study of systemic pegcetacoplan for CAD.
  • Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA): Sobi continues to enroll patients in its Phase 2 study evaluating the efficacy and safety of systemic pegcetacoplan in patients with HSCT-TMA. Data from this study is expected in the second half of 2023.
  • EMPAVELI + small interfering RNA (siRNA): Apellis is studying the combination of EMPAVELI and an siRNA in pre-clinical studies, which may offer the potential to reduce the treatment frequency of EMPAVELI. Apellis expects to submit an IND application for its siRNA in the first half of 2023.


Neurology


R&D Highlights

  • APL-1030: Apellis continues to advance pre-clinical studies with APL-1030, a first-in-class, brain-active C3 inhibitor for neurological diseases.

Fourth Quarter and Full Year 2022 Financial Results:

Cash. As of December 31, 2022, Apellis had $551.8 million in cash and cash equivalents, compared to $700.6 million in cash, cash equivalents, and short-term marketable securities as of December 31, 2021.

Total Revenue.

  • Total revenue was $22.7 million for the fourth quarter of 2022, which consisted of $19.7 million of U.S. net product revenue of EMPAVELI and additional licensing and other revenue associated with the Sobi collaboration. Total revenue was $60.3 million for the fourth quarter of 2021, which consisted of $9.2 million in U.S. net product revenue of EMPAVELI and $51.1 million in revenue associated with the $50.0 milestone and additional licensing and other revenue from the Sobi collaboration.
  • For the full year 2022, total revenue was $75.4 million, which consisted of $65.1 million of U.S. net product revenue of EMPAVELI and additional licensing and other revenue associated with the Sobi collaboration. For the full year 2021, total revenue was $66.6 million, which consisted of $15.1 million in U.S. net product revenue of EMPAVELI and $51.4 million in revenue associated with the $50.0 milestone and additional licensing and other revenue from the Sobi collaboration.

Cost of Sales.

  • Cost of sales were $5.6 million and $0.2 million for the full year 2022 and 2021, respectively. Cost of sales consists primarily of costs associated with the manufacturing of EMPAVELI, royalties owed to our licensor for such sales, and certain period costs.
    • Prior to receiving FDA approval for EMPAVELI in May 2021, costs associated with the manufacturing of EMPAVELI inventory were expensed as research and development (R&D) expense. This resulted in inventory being sold during the years ended December 31, 2022 and 2021 for which a portion of the costs had been previously expensed prior to FDA approval.

R&D Expenses.

  • R&D expenses were $99.4 million for the fourth quarter of 2022, compared to $108.2 million for the same period in 2021. For the full year ended December 31, 2022, R&D expenses were $387.2 million compared to $425.9 million for the full year ended December 31, 2021.
  • The decrease in R&D expenses for the full year ended December 31, 2022 was primarily attributable to $75.0 million associated with the Beam collaboration and the $5.0 million licensee fee to the University of Pennsylvania related to the Sobi transaction recorded in 2021, a decrease in clinical contract manufacturing expenses due primarily to the timing of drug supply and analytical activity, and a decrease in clinical trial costs due to the completion of our Phase 3 OAKS and DERBY trials. These decreases were offset by higher personnel related costs due to having more employees as of December 31, 2022, higher research and innovation costs, and higher other research and development supporting activities. In addition, contra research and development expenses under the Sobi collaboration were $5.0 million for the year ended December 31, 2022 compared to $32.0 million for the year ended December 31, 2021.

General and Administrative (G&A) Expenses.

  • G&A expenses were $84.4 million for the fourth quarter of 2022, compared to $41.5 million for the same period in 2021. For the full year ended December 31, 2022, G&A expenses were $277.2 million compared to $176.8 million for the full year ended December 31, 2021.
  • The increase in G&A expenses for the full year ended December 31, 2022 was primarily attributable to an increase in employee related costs and increases in costs related to general commercial preparation activities.

Net Loss (Income). Apellis reported a net loss of $166.0 million and $652.2 million for the fourth quarter and full year 2022, respectively, compared to a net loss of $147.9 million and $746.4 million for the same periods in 2021.

About SYFOVRE™ (pegcetacoplan injection)

SYFOVRE™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to age-related macular degeneration.

About EMPAVELI

®

(pegcetacoplan)
EMPAVELI® (pegcetacoplan) is the first and only approved therapy for PNH targeting C3, the central protein in the complement cascade. EMPAVELI acts proximally in the complement cascade controlling both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis. EMPAVELI is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).


U.S. Important Safety Information for SYFOVRE™ (pegcetacoplan injection)


CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation
    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure
    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see accompanying full Prescribing Information for more information.


U.S. Important Safety Information for EMPAVELI

BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

  • Meningococcal infections may occur in patients treated with EMPAVELI and may become rapidly life-threatening or fatal if not recognized and treated early. Use of EMPAVELI may predispose individuals to serious infections, especially those caused by encapsulated bacteria, such as

    Streptococcus pneumoniae

    ,

    Neisseria meningitidis

    types A, C, W, Y, and B, and

    Haemophilus influenzae

    type B.
  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria.
  • Vaccinate patients at least 2 weeks prior to administering the first dose of EMPAVELI unless the risks of delaying therapy with EMPAVELI outweigh the risk of developing a serious infection.
  • Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected.
  • EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the EMPAVELI REMS, prescribers must enroll in the program.

CONTRAINDICATIONS

  • Hypersensitivity to pegcetacoplan or to any of the excipients
  • Not currently vaccinated against certain encapsulated bacteria, unless the risks of delaying EMPAVELI treatment outweigh the risks of developing a bacterial infection with an encapsulated organism
  • Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

The use of EMPAVELI may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI.

For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of EMPAVELI. If immediate therapy with EMPAVELI is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.

Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI REMS

Because of the risk of serious infections, EMPAVELI is available only through a restricted program under a REMS. Under the EMPAVELI REMS, prescribers must enroll in the program and must counsel patients about the risk of serious infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria. Enrollment and additional information are available by telephone: 1-888-343-7073 or at www.empavelirems.com.

Infusion-Related Reactions

Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with EMPAVELI. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Monitoring PNH Manifestations after Discontinuation of EMPAVELI

After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.

Interference with Laboratory Tests

There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS

Most common adverse reactions in patients with PNH (incidence ≥10%) were injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, pain in extremity, hypokalemia, fatigue, viral infection, cough, arthralgia, dizziness, headache, and rash.

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential

EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full

Prescribing Information

, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and

Medication Guide

.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Apellis Forward-Looking Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether SYFOVRE will be commercially available when expected; whether clinical trials of SYFOVRE indicate an apparent positive effect that is greater than the actual positive effect, whether SYFOVRE will receive approval from foreign regulatory agencies for GA when expected or at all; whether the company’s clinical trials will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether pegcetacoplan will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company’s clinical trials will warrant regulatory submissions and whether systemic pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for CAD, C3G, IC-MPGN, HSCT-TMA, ALS or any other indication when expected or at all; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 21, 2023 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:
Lissa Pavluk
[email protected]
617.977.6764

Investor Contact:

Meredith Kaya
[email protected]
617.599.8178

APELLIS PHARMACEUTICALS, INC.    
CONDENSED CONSOLIDATED BALANCE SHEETS    
(Amounts in thousands, except per share amounts)    
  December 31,   December 31,
    2022       2021  
Assets (Unaudited)    
Current assets:      
Cash and cash equivalents $ 551,801     $ 640,192  
Marketable securities         60,358  
Accounts receivable   7,727       10,103  
Inventory   85,714       16,286  
Prepaid assets   36,350       24,868  
Restricted cash   1,273       1,563  
Other current assets   36,658       70,677  
Total current assets   719,523       824,047  
Non-current assets:      
Right-of-use assets   18,747       19,901  
Property and equipment, net   6,148       6,177  
Other assets   15,799       31,640  
Total assets $ 760,217     $ 881,765  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable   37,342     $ 16,909  
Accrued expenses   95,139       103,239  
Current portion of development liability   29,504       7,584  
Current portion of right of use liabilities   5,625       4,115  
Total current liabilities   167,610       131,847  
Long-term liabilities:      
Long-term development liability   315,647       345,151  
Convertible senior notes   92,736       189,024  
Right-of-use liabilities   14,352       17,081  
Total liabilities   590,345       683,103  
Commitments and contingencies (Note 16)      
Stockholders’ equity:      
Preferred stock, $0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at December 31, 2022 and 2021          
Common stock, $0.0001 par value; 200,000 shares authorized at December 31, 2022 and 2021; 110,772 and 97,524 shares issued and outstanding at December 31, 2022 and 2021   11       10  
Additional paid-in capital   2,479,596       1,857,430  
Accumulated other comprehensive loss   (875 )     (2,090 )
Accumulated deficit   (2,308,860 )     (1,656,688 )
Total stockholders’ equity   169,872       198,662  
Total liabilities and stockholders’ equity $ 760,217     $ 881,765  
       

APELLIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Amounts in thousands, except per share amounts)
               
  For the Three Months Ended December 31,   Year Ended December 31,
    2022       2021       2022       2021  
  (Unaudited)   (Unaudited)
Revenue:              
Product revenue, net $ 19,653     $ 9,210     $ 65,092     $ 15,147  
Licensing and other revenue   3,010       51,080     $ 10,330     $ 51,416  
Total revenue:   22,663       60,290       75,422       66,563  
Operating expenses:              
Cost of sales   2,925       45       5,636       200  
Research and development   99,423       78,180       387,236       345,869  
Cost of research collaboration         25,000             75,000  
License expense         5,000             5,000  
General and administrative   84,368       41,462       277,163       176,771  
Operating expenses:   186,716       149,687       670,035       602,840  
Net operating income/(loss)   (164,053 )     (89,397 )     (594,613 )     (536,277 )
Loss on conversion of debt               (32,890 )     (100,589 )
Loss from remeasurement of development derivative liability         (55,192 )           (97,675 )
Interest income   4,575       37       8,914       418  
Interest expense   (7,738 )     (3,018 )     (32,626 )     (13,241 )
Other (expense)/income, net   (246 )     (169 )     (288 )     1,362  
Net loss before taxes   (167,462 )     (147,739 )     (651,503 )     (746,002 )
Income tax expense   (1,471 )     196       669       352  
Net income/(loss) $ (165,991 )   $ (147,935 )   $ (652,172 )   $ (746,354 )
Other comprehensive (loss)/gain:              
Unrealized (loss)/gain on marketable securities   382       9       (1 )     9  
Unrealized gain on pension plans   1,646             1,646        
Foreign currency gain/(loss)   124       71       (430 )     (1,982 )
Total other comprehensive income/(loss)   2,152       80       1,215       (1,973 )
Comprehensive loss, net of tax $ (163,839 )   $ (147,855 )   $ (650,957 )   $ (748,327 )
Net loss per common share, basic and diluted $ (1.50 )   $ (1.61 )   $ (6.15 )   $ (8.84 )
Weighted-average number of common shares used in net loss per common share, basic and diluted   110,629       92,149       106,114       84,421  
               

 

 



Coinbase Releases Fourth Quarter and Full Year 2022 Shareholder Letter

Coinbase Releases Fourth Quarter and Full Year 2022 Shareholder Letter

REMOTE-FIRST-COMPANY/LOS ANGELES–(BUSINESS WIRE)–
Coinbase Global, Inc. (the “Company” or “Coinbase”) announced today the release of its fourth quarter and full year 2022 shareholder letter. The letter, including the Company’s financial results, can be found on its Investor Relations website at investor.coinbase.com.

The Company will hold a question and answer session to discuss its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023 at 2:30 p.m. PT.

To register for the webcast, please use this link. A live webcast of the call will be available on the Investor Relations website at investor.coinbase.com. Following the call, a replay of the call, as well as a transcript, will be available on the same website.

Disclosure Information

Coinbase uses the investor.coinbase.com and blog.coinbase.com websites, as well as press releases, public conference calls, public webcasts, our Twitter feed (@coinbase), our Facebook page, our LinkedIn page, our YouTube channel, and Brian Armstrong’s Twitter feed (@brian_armstrong) as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

About Coinbase

Coinbase is building the cryptoeconomy – a more fair, accessible, efficient, and transparent financial system enabled by crypto. The company started in 2012 with the radical idea that anyone, anywhere, should be able to easily and securely send and receive Bitcoin. Today, Coinbase offers a trusted and easy-to-use platform for accessing the broader cryptoeconomy.

Press:

[email protected]

Investor Relations:

[email protected]

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Technology Finance Security Fintech Professional Services Software Networks Internet Cryptocurrency

MEDIA:

Logo
Logo

Archrock Reports Fourth Quarter and Full Year 2022 Results and Provides 2023 Guidance

HOUSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Archrock, Inc. (NYSE: AROC) (“Archrock”) today reported results for the fourth quarter and full year 2022 and provided 2023 financial guidance.

Fourth Quarter and Full Year 2022 Highlights

  • Revenue for the fourth quarter of 2022 was $218.9 million compared to $195.2 million in the fourth quarter of 2021. Revenue for 2022 was $845.6 million compared to $781.5 million in 2021.
  • Net income for the fourth quarter of 2022 was $10.5 million compared to $6.0 million in the fourth quarter of 2021. Net income for 2022 was $44.3 million compared to $28.2 million in 2021.
  • Adjusted EBITDA (a non-GAAP measure defined below) for the fourth quarter of 2022 was $89.0 million compared to $83.5 million in the fourth quarter of 2021. Adjusted EBITDA for 2022 was $363.3 million compared to $360.8 million in 2021.
  • Declared a quarterly dividend of $0.15 per common share for the fourth quarter of 2022, an increase of 3 percent over the third quarter 2022 level. Dividend coverage for 2022 was 1.9x compared to 2.2x in 2021.
  • Achieved record period-end utilization of 93% for the fourth quarter of 2022 compared to 84% in the fourth quarter of 2021.

Management Commentary and Outlook

“We closed out 2022 with significant operating momentum and solid financial performance,” said Brad Childers, Archrock’s President and Chief Executive Officer. “For the full year 2022, we grew operating horsepower by approximately 375,000 horsepower, excluding non-strategic asset sales, drove a 900 basis point increase in our period-end utilization to 93% and generated net income and earnings per share growth. We also continued to divest small, non-strategic compressors, and, as a result, large horsepower now represents 84% of our total fleet.

“Our 2023 outlook reflects progress on our strategic transformation and market fundamentals for the compression industry that are as exciting as I have ever seen. This includes record utilization, significantly higher pricing and enhanced profitability, which at the midpoint of our guidance translates into adjusted EBITDA growth of more than $50 million compared to 2022. Our focus in the coming year will be on demonstrating our earnings power through excellent operating execution – efficiently and profitably capturing robust demand for compression, continuing to deliver a first-rate customer experience, harnessing our upgraded technology platform and high-graded asset base and prioritizing opportunities to help our customers with emissions management.

“Turning to capital allocation, our conviction in a multi-year upcycle for compression and Archrock’s strategy drove the decision to resume dividend growth, beginning with the February 2023 payment. With proactive debt reduction of more than $300 million since the end of 2019 and a visible inflection point in our financial performance, we expect to achieve a leverage ratio of below 4.0 times as well as dividend coverage of approximately 2.0 times during 2023. At the same time, as the demand for compression exceeds available equipment, we plan to capitalize on the opportunity to redeploy the proceeds received from non-strategic asset sales for investment in large horsepower compression units. I am confident that the strength of our people, assets and strategy will drive continued and increased shareholder value and returns in 2023 and beyond,” concluded Childers.  

Fourth Quarter and Full Year 2022 Financial Results

Archrock’s fourth quarter 2022 net income of $10.5 million included a non-cash long-lived and other asset impairment of $5.2 million and a non-cash unrealized change in the fair value of our investment in an unconsolidated affiliate of $1.9 million. Archrock’s fourth quarter 2021 net income of $6.0 million included a non-cash long-lived and other asset impairment of $6.2 million and restructuring costs of $950,000, partially offset by an insurance settlement related to damages to facilities and compressors caused by Hurricane Ida of $2.8 million.

Adjusted EBITDA for the fourth quarter of 2022 and 2021 included $6.7 million and $0.7 million, respectively, in net gains related to the sale of compression and other assets.

Archrock’s full year 2022 net income of $44.3 million included the following items: non-cash long-lived and other asset impairment of $21.4 million and a non-cash unrealized change in the fair value of our investment in an unconsolidated affiliate of $1.9 million. Archrock’s full year 2021 net income of $28.2 million included the following items: non-cash long-lived and other asset impairment of $21.4 million, restructuring costs related to severance and property exit and disposals totaling $2.9 million, a non-cash write-off of unamortized deferred financing costs of $4.9 million, non-cash depreciation expense from the write-off of assets damaged in Hurricane Ida of $2.0 million and a non-income-based tax benefit of $2.5 million.

Adjusted EBITDA for the full year 2022 and 2021 included $40.5 million and $30.3 million, respectively, in net gains related to the sale of compression and other assets.


Contract Operations

For the fourth quarter of 2022, contract operations segment revenue totaled $177.4 million, an increase of 11% compared to $159.5 million in the fourth quarter of 2021. Gross margin was $103.0 million, up from $99.0 million in the fourth quarter of 2021. This reflected a gross margin percentage of 58%, compared to 62% in the fourth quarter of 2021. Total operating horsepower at the end of the fourth quarter of 2022 was 3.4 million compared with 3.2 million at the end of the fourth quarter of 2021, and reflected the sale of 176,000 active horsepower as part of our ongoing fleet high-grading initiative. Utilization at the end of the fourth quarter of 2022 was 93%, compared to 84% at the end of the fourth quarter of 2021.


Aftermarket Services

For the fourth quarter of 2022, aftermarket services segment revenue totaled $41.5 million, an increase of 16% compared to $35.7 million in the fourth quarter of 2021, driven by higher parts sales and service activity. Gross margin of $7.1 million increased 36% compared to $5.2 million in the fourth quarter of 2021. Gross margin percentage was 17%, up from 15% in the prior year quarter.

Balance Sheet

Long-term debt was $1.5 billion at December 31, 2022 and our available liquidity totaled $487.6 million. Our leverage ratio was 4.4x, compared to 4.3x as of December 31, 2021.

Quarterly Dividend

Our Board of Directors recently declared an increased quarterly dividend of $0.15 per share of common stock, or $0.60 per share on an annualized basis. The fourth quarter 2022 dividend per share amount represents an increase of 3 percent over the Archrock third quarter 2022 dividend level. Dividend coverage in the fourth quarter of 2022 was 1.5x and for the full-year 2022 was 1.9x. The fourth quarter 2022 dividend was paid on February 14, 2023 to stockholders of record at the close of business on February 7, 2023.

2023 Annual Guidance

Archrock is providing annual guidance as listed below. All figures are in thousands, except percentages and ratios:

  Full Year 2023 Guidance
  Low   High
Net income (1)  $ 75,000     $ 105,000  
Adjusted EBITDA(2)   400,000       430,000  
Cash available for dividend(3)(4)   202,000       227,000  
               
Segment              
Contract operations revenue $ 775,000     $ 800,000  
Contract operations gross margin percentage(5)   60 %     62 %
Aftermarket services revenue $ 170,000     $ 180,000  
Aftermarket services gross margin percentage   17 %     18.5 %
               
Selling, general and administrative(5) $ 106,000     $ 104,000  
               
Capital expenditures              
Growth capital expenditures $ 180,000     $ 200,000  
Maintenance capital expenditures   75,000       80,000  
Other capital expenditures   15,000       15,000  
               

_______________
(1) 2023 annual guidance for net income does not include the impact of long-lived and other asset impairment because due to its nature, it cannot be accurately forecasted. Long-lived and other asset impairment does not impact Adjusted EBITDA or cash available for dividend, however it is a reconciling item between these measures and net income. Long-lived and other asset impairment for both 2022 and 2021 was $21.4 million.
(2) Management believes Adjusted EBITDA provides useful information to investors because this non-GAAP measure, when viewed with our GAAP results and accompanying reconciliations, provides a more complete understanding of our performance than GAAP results alone. Management uses this non-GAAP measure as a supplemental measure to review current period operating performance, comparability measure and performance measure for period-to-period comparisons.
(3) Management uses cash available for dividend as a supplemental performance measure to compute the coverage ratio of estimated cash flows to planned dividends.
(4) A forward-looking estimate of cash provided by operating activities is not provided because certain items necessary to estimate cash provided by operating activities, including changes in assets and liabilities, are not estimable at this time. Changes in assets and liabilities were $(24.5) million and $(9.5) million for 2022 and 2021, respectively.
(5) 2023 annual guidance reflects the change in tax compliance for approximately $10 million of sales taxes associated with contract operations cost of sales; these costs will be accounted for in contract operations cost of sales in 2023 but were accounted for in selling, general and administrative costs during 2022 and 2021.

Summary Metrics

(in thousands, except percentages, per share amounts and ratios)

  Three Months Ended   Year Ended
  December 31,    September 30,    December 31,    December 31,    December 31, 
  2022   2022   2021   2022   2021
Net income $ 10,458     $ 15,371     $ 5,992     $ 44,296     $ 28,217  
Adjusted EBITDA $ 89,040     $ 91,919     $ 83,499     $ 363,325     $ 360,809  
                                 
Contract operations revenue $ 177,350     $ 170,497     $ 159,501     $ 677,801     $ 648,311  
Contract operations gross margin $ 103,002     $ 98,803     $ 99,047     $ 398,903     $ 403,825  
Contract operations gross margin percentage   58 %     58 %     62 %     59 %     62 %
                                 
Aftermarket services revenue $ 41,521     $ 43,171     $ 35,748     $ 167,767     $ 133,150  
Aftermarket services gross margin $ 7,116     $ 7,338     $ 5,242     $ 27,181     $ 18,719  
Aftermarket services gross margin percentage   17 %     17 %     15 %     16 %     14 %
                                 
Selling, general, and administrative $ 31,220     $ 30,500     $ 27,167     $ 117,184     $ 107,167  
                                 
Cash available for dividend $ 34,898     $ 41,354     $ 45,545     $ 170,908     $ 199,838  
Cash available for dividend coverage   1.5 x     1.8 x     2.0 x     1.9 x     2.2 x
                                 
Free cash flow $ (27,252 )   $ 56,296     $ 6,928       72,534       253,507  
Free cash flow after dividend $ (49,841 )   $ 33,737     $ (15,423 )     (17,781 )     164,164  
                                 
Total available horsepower (at period end)   3,726       3,747       3,878                
Total operating horsepower (at period end)   3,448       3,353       3,247                
Horsepower utilization spot (at period end)   93 %     89 %     84 %              
                                     

Conference Call Details

Archrock will host a conference call on Wednesday, February 22, 2023, to discuss fourth quarter and full year 2022 financial results and 2023 guidance. The call will begin at 12:00 p.m. Eastern Time.

To listen to the call via a live webcast, please visit Archrock’s website at www.archrock.com. The call will also be available by dialing 1-888-440-5667 in the United States and Canada or 1-646-960-0476 for international calls. The access code is 4749623.

A replay of the webcast will be available on Archrock’s website for 90 days following the event.

Adjusted EBITDA, a non–GAAP measure, is defined as net income (loss) excluding interest expense, income taxes, depreciation and amortization, long–lived and other asset impairment, unrealized change in fair value of investment in unconsolidated affiliate, restructuring charges, non–cash stock–based compensation expense, amortization of capitalized implementation costs and other items. A reconciliation of Adjusted EBITDA to net income, the most directly comparable GAAP measure, and a reconciliation of our full year 2022 Adjusted EBITDA guidance to net income appear below.

Gross margin, a non–GAAP measure, is defined as revenue less cost of sales (excluding depreciation and amortization). Gross margin percentage is defined as gross margin divided by revenue. A reconciliation of gross margin to net income, the most directly comparable GAAP measure, appears below.

Cash available for dividend, a non–GAAP measure, is defined as net income (loss) excluding interest expense, income taxes, depreciation and amortization, long–lived and other asset impairment, unrealized change in fair value of investment in unconsolidated affiliate, restructuring charges, non–cash stock–based compensation expense, amortization of capitalized implementation costs and other items, less maintenance capital expenditures, other capital expenditures, cash taxes and cash interest expense. Reconciliations of cash available for dividend to net income and net cash provided by operating activities, the most directly comparable GAAP measures, and a reconciliation of our updated full year 2022 cash available for dividend guidance to net income appear below.

Free cash flow, a non–GAAP measure, is defined as net cash provided by operating activities plus net cash provided by (used in) investing activities. A reconciliation of free cash flow to net cash provided by operating activities, the most directly comparable GAAP measure, appears below.

Free cash flow after dividend, a non–GAAP measure, is defined as net cash provided by operating activities plus net cash provided by (used in) investing activities less dividends paid to stockholders. A reconciliation of free cash flow after dividend to net cash provided by operating activities, the most directly comparable GAAP measure, appears below.

About Archrock

Archrock is an energy infrastructure company with a primary focus on midstream natural gas compression and a commitment to helping its customers produce, compress and transport natural gas in a safe and environmentally responsible way. Headquartered in Houston, Texas, Archrock is the leading provider of natural gas compression services to customers in the energy industry throughout the U.S. and a leading supplier of aftermarket services to customers that own compression equipment. For more information on how Archrock embodies its purpose, WE POWER A CLEANER AMERICA, visit www.archrock.com.

Forward–Looking Statements

All statements in this release (and oral statements made regarding the subjects of this release) other than historical facts are forward–looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward–looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors that could cause actual results to differ materially from such statements, many of which are outside the control of Archrock, Inc. Forward–looking information includes, but is not limited to statements regarding: guidance or estimates related to Archrock’s results of operations or of financial condition; fundamentals of Archrock’s industry, including the attractiveness of returns and valuation, stability of cash flows, demand dynamics and overall outlook, and Archrock’s ability to realize the benefits thereof; Archrock’s expectations regarding future economic, geopolitical and market conditions and trends; Archrock’s operational and financial strategies, including planned growth, coverage and leverage reduction strategies, Archrock’s ability to successfully effect those strategies and the expected results therefrom; Archrock’s development and deployment of new technologies and the expected results therefrom; Archrock’s financial and operational outlook; demand and growth opportunities for Archrock’s services; structural and process improvement initiatives, the expected timing thereof, Archrock’s ability to successfully effect those initiatives and the expected results therefrom; the operational and financial synergies provided by Archrock’s size; Archrock’s ability to integrate ECOTEC’s products and services into its business and offer them to its customers; and statements regarding Archrock’s dividend policy.

While Archrock believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in predicting certain important factors that could impact the future performance or results of its business. The factors that could cause results to differ materially from those indicated by such forward–looking statements include, but are not limited to: changes in customer, employee or supplier relationships; local, regional and national economic and financial market conditions and the impact they may have on Archrock and its customers; changes in tax laws; conditions in the oil and gas industry, including a sustained decrease in the level of supply or demand for oil or natural gas or a sustained decrease in the price of oil or natural gas; changes in economic conditions in key operating markets; impacts of world events; the financial condition of Archrock’s customers; the failure of any customer to perform its contractual obligations; changes in safety, health, environmental and other regulations; and the effectiveness of Archrock’s control environment, including the identification of control deficiencies.

These forward–looking statements are also affected by the risk factors, forward–looking statements and challenges and uncertainties described in Archrock’s Annual Report on Form 10–K for the year ended December 31, 2021, Archrock’s Quarterly Reports on Form 10–Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022, and those set forth from time to time in Archrock’s filings with the Securities and Exchange Commission, which are available at www.archrock.com. Except as required by law, Archrock expressly disclaims any intention or obligation to revise or update any forward–looking statements whether as a result of new information, future events or otherwise.

SOURCE: Archrock, Inc.


For information, contact:

Megan Repine
VP of Investor Relations
281–836–8360
[email protected]

Archrock, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

  Three Months Ended   Year Ended
  December 31,    September 30,    December 31,    December 31,    December 31, 
  2022   2022   2021   2022   2021
Revenue:                            
Contract operations $ 177,350     $ 170,497     $ 159,501     $ 677,801     $ 648,311  
Aftermarket services   41,521       43,171       35,748       167,767       133,150  
Total revenue   218,871       213,668       195,249       845,568       781,461  
                             
Cost of sales (excluding depreciation and amortization):                            
Contract operations   74,348       71,694       60,454       278,898       244,486  
Aftermarket services   34,405       35,833       30,506       140,586       114,431  
Total cost of sales (excluding depreciation and amortization)   108,753       107,527       90,960       419,484       358,917  
                             
Selling, general and administrative   31,220       30,500       27,167       117,184       107,167  
Depreciation and amortization   39,911       39,953       43,761       164,259       178,946  
Long-lived and other asset impairment   5,225       4,154       6,243       21,442       21,397  
Restructuring charges               950             2,903  
Interest expense   26,380       25,177       25,424       101,259       108,135  
Gain on sale of assets, net   (6,739 )     (12,695 )     (709 )     (40,494 )     (30,258 )
Other (income) expense, net   1,897       (585 )     (3,073 )     1,845       (4,707 )
Income before income taxes   12,224       19,637       4,526       60,589       38,961  
Provision for (benefit from) income taxes   1,766       4,266       (1,466 )     16,293       10,744  
Net income $ 10,458     $ 15,371     $ 5,992     $ 44,296     $ 28,217  
                             
Basic and diluted net income per common share (1) $ 0.07     $ 0.10     $ 0.04     $ 0.28     $ 0.18  
                             
Weighted average common shares outstanding:                            
Basic   153,554       153,550       152,320       153,281       151,684  
Diluted   153,682       153,687       152,442       153,410       151,830  
                                       

 

_______________
(1) Basic and diluted net income per common share is computed using the two–class method to determine the net income per share for each class of common stock and participating security (restricted stock and stock–settled restricted stock units that have non–forfeitable rights to receive dividends or dividend equivalents) according to dividends declared and participation rights in undistributed earnings. Accordingly, we have excluded net income attributable to participating securities from our calculation of basic and diluted net income per common share.

Archrock, Inc.

Unaudited Supplemental Information

(in thousands, except percentages, per share amounts and ratios)

  Three Months Ended   Year Ended
  December 31,    September 30,    December 31,    December 31,    December 31, 
  2022   2022   2021   2022   2021
Revenue:                            
Contract operations $ 177,350     $ 170,497     $ 159,501     $ 677,801     $ 648,311  
Aftermarket services   41,521       43,171       35,748       167,767       133,150  
Total revenue $ 218,871     $ 213,668     $ 195,249     $ 845,568     $ 781,461  
                             
Gross margin (1):                            
Contract operations $ 103,002     $ 98,803     $ 99,047     $ 398,903     $ 403,825  
Aftermarket services   7,116       7,338       5,242       27,181       18,719  
Total gross margin $ 110,118     $ 106,141     $ 104,289     $ 426,084     $ 422,544  
                             
Gross margin percentage:                            
Contract operations   58 %     58 %     62 %     59 %     62 %
Aftermarket services   17 %     17 %     15 %     16 %     14 %
Total gross margin percentage   50 %     50 %     53 %     50 %     54 %
                             
Selling, general and administrative $ 31,220     $ 30,500     $ 27,167     $ 117,184     $ 107,167  
% of revenue   14 %     14 %     14 %     14 %     14 %
                             
Adjusted EBITDA (1) $ 89,040     $ 91,919     $ 83,499     $ 363,325     $ 360,809  
% of revenue   41 %     43 %     43 %     43 %     46 %
                             
Capital expenditures $ 68,835     $ 64,966     $ 27,004     $ 239,867     $ 97,885  
Proceeds from sale of property, plant and equipment and other assets   (7,132 )     (44,262 )     (5,149 )     (120,265 )     (112,907 )
Net capital expenditures $ 61,703     $ 20,704     $ 21,855     $ 119,602     $ (15,022 )
                             
Total available horsepower (at period end) (2)   3,726       3,747       3,878       3,726       3,878  
Total operating horsepower (at period end) (3)   3,448       3,535       3,247       3,448       3,247  
Average operating horsepower   3,394       3,355       3,220       3,328       3,282  
Horsepower utilization:                            
Spot (at period end)   93 %     89 %     84 %     93 %     84 %
Average   91 %     88 %     83 %     87 %     82 %
                             
Dividend declared for the period per share $ 0.150     $ 0.145     $ 0.145     $ 0.580     $ 0.580  
Dividend declared for the period to all shareholders $ 23,614     $ 22,645     $ 22,598     $ 91,340     $ 89,590  
Cash available for dividend coverage (4)   1.5 x     1.8 x     2.0 x     1.9 x     2.2 x
                             
Free cash flow (1) $ (27,252 )   $ 56,296     $ 6,928     $ 72,534     $ 253,507  
Free cash flow after dividend (1) $ (49,841 )   $ 33,737     $ (15,423 )   $ (17,781 )   $ 164,164  
                                       

_______________
(1) Management believes gross margin, Adjusted EBITDA, free cash flow and free cash flow after dividend provide useful information to investors because these non–GAAP measures, when viewed with our GAAP results and accompanying reconciliations, provide a more complete understanding of our performance than GAAP results alone. Management uses these non–GAAP measures as supplemental measures to review current period operating performance, comparability measures and performance measures for period–to–period comparisons.(2) Defined as idle and operating horsepower, and includes new compressor units completed by a third party manufacturer that have been delivered to us.
(3) Defined as horsepower that is operating under contract and horsepower that is idle but under contract and generating revenue such as standby revenue.
(4) Defined as cash available for dividend divided by dividends declared for the period.

  December 31,    September 30,    December 31, 
  2022      2022      2021
Balance Sheet                      
Long-term debt (1) $ 1,548,334     $ 1,498,895     $ 1,530,825  
Total equity   860,693       869,816       891,438  
                       

_______________
(1) Carrying values are shown net of unamortized premium and deferred financing costs.

Archrock, Inc.

Unaudited Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA and Gross Margin

(in thousands)

  Three Months Ended   Year Ended
  December 31,    September 30,    December 31,    December 31,    December 31, 
  2022   2022   2021   2022   2021
Net income $ 10,458     $ 15,371     $ 5,992     $ 44,296     $ 28,217  
Depreciation and amortization   39,911       39,953       43,761       164,259       178,946  
Long-lived and other asset impairment   5,225       4,154       6,243       21,442       21,397  
Unrealized change in fair value of investment in unconsolidated affiliate   1,864                   1,864        
Restructuring charges               950             2,903  
Interest expense   26,380       25,177       25,424       101,259       108,135  
Stock-based compensation expense   2,893       2,998       2,595       11,928       11,336  
Amortization of capitalized implementation costs (1)   543                   1,984        
Indemnification income, net                           (869 )
Provision for (benefit from) income taxes   1,766       4,266       (1,466 )     16,293       10,744  
Adjusted EBITDA (2)   89,040       91,919       83,499       363,325       360,809  
Selling, general and administrative   31,220       30,500       27,167       117,184       107,167  
Stock-based compensation expense   (2,893 )     (2,998 )     (2,595 )     (11,928 )     (11,336 )
Amortization of capitalized implementation costs   (543 )                 (1,984 )      
Unrealized change in fair value of investment in unconsolidated affiliate   (1,864 )                 (1,864 )      
Indemnification income, net                           869  
Gain on sale of assets, net   (6,739 )     (12,695 )     (709 )     (40,494 )     (30,258 )
Other (income) expense, net   1,897       (585 )     (3,073 )     1,845       (4,707 )
Gross margin (2) $ 110,118     $ 106,141     $ 104,289     $ 426,084     $ 422,544  
                                       

_______________
(1) The amortization of capitalized implementation costs is a new adjustment beginning in the fourth quarter of 2022; as such, only the amounts for the fourth quarter of 2022 and full year 2022 have been included.
(2) Management believes Adjusted EBITDA and gross margin provide useful information to investors because these non–GAAP measures, when viewed with our GAAP results and accompanying reconciliations, provide a more complete understanding of our performance than GAAP results alone. Management uses these non–GAAP measures as supplemental measures to review current period operating performance, comparability measures and performance measures for period–to–period comparisons.

Archrock, Inc.

Unaudited Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA and Cash Available for Dividend

(in thousands)

  Three Months Ended   Year Ended
  December 31,    September 30,    December 31,    December 31,    December 31, 
  2022   2022   2021   2022   2021
Net income $ 10,458     $ 15,371     $ 5,992     $ 44,296     $ 28,217  
Depreciation and amortization   39,911       39,953       43,761       164,259       178,946  
Long-lived and other asset impairment   5,225       4,154       6,243       21,442       21,397  
Unrealized change in fair value of investment in unconsolidated affiliate   1,864                   1,864        
Restructuring charges               950             2,903  
Interest expense   26,380       25,177       25,424       101,259       108,135  
Stock-based compensation expense   2,893       2,998       2,595       11,928       11,336  
Amortization of capitalized implementation costs (1)   543                   1,984        
Indemnification income, net                           (869 )
Provision for (benefit from) income taxes   1,766       4,266       (1,466 )     16,293       10,744  
Adjusted EBITDA (2)   89,040       91,919       83,499       363,325       360,809  
Less: Maintenance capital expenditures   (24,695 )     (24,084 )     (11,883 )     (84,158 )     (47,346 )
Less: Other capital expenditures   (3,849 )     (2,091 )     (1,789 )     (9,446 )     (13,376 )
Less: Cash tax payment   (4 )           358       (407 )     (247 )
Less: Cash interest expense   (25,594 )     (24,390 )     (24,640 )     (98,406 )     (100,002 )
Cash available for dividend (3) $ 34,898     $ 41,354     $ 45,545     $ 170,908     $ 199,838  
                                       

_______________
(1) The amortization of capitalized implementation costs is a new adjustment beginning in the fourth quarter of 2022; as such, only the amounts for the fourth quarter of 2022 and full year 2022 have been included.
(2) Management believes Adjusted EBITDA provides useful information to investors because this non–GAAP measure, when viewed with our GAAP results and accompanying reconciliations, provides a more complete understanding of our performance than GAAP results alone. Management uses this non–GAAP measure as a supplemental measure to review current period operating performance, comparability measure and performance measure for period–to–period comparisons.
(3) Management uses cash available for dividend as a supplemental performance measure to compute the coverage ratio of estimated cash flows to planned dividends.

Archrock, Inc.

Unaudited Supplemental Information

Reconciliation of Cash Flows from Operating Activities to Cash Available for Dividend

(in thousands)

  Three Months Ended   Year Ended
  December 31,    September 30,    December 31,    December 31,    December 31, 
  2022   2022   2021   2022   2021
Net cash provided by operating activities $ 37,118     $ 76,808     $ 28,675     $ 203,450     $ 237,400  
Inventory write-downs   (600 )     (319 )     (376 )     (1,640 )     (997 )
Provision for (benefit from) credit losses   (234 )     393       241       (206 )     90  
Gain on sale of assets, net   6,739       12,695       709       40,494       30,258  
Current income tax provision (benefit)   161       115       (67 )     1,064       365  
Cash tax refund (payment)   (4 )           358       (407 )     (247 )
Amortization of operating lease ROU assets   (799 )     (832 )     (958 )     (3,206 )     (3,880 )
Amortization of contract costs   (4,951 )     (4,962 )     (4,467 )     (19,162 )     (19,990 )
Deferred revenue recognized in earnings   5,247       4,168       2,301       20,956       10,382  
Cash restructuring charges               950             2,903  
Indemnification income, net                           (869 )
Changes in assets and liabilities   20,765       (20,537 )     32,958       24,503       9,535  
Maintenance capital expenditures   (24,695 )     (24,084 )     (11,883 )     (84,158 )     (47,346 )
Other capital expenditures   (3,849 )     (2,091 )     (1,789 )     (9,446 )     (13,376 )
Payments for settlement of interest rate swaps that include financing elements               (1,107 )     (1,334 )     (4,390 )
Cash available for dividend (1) $ 34,898     $ 41,354     $ 45,545     $ 170,908     $ 199,838  
                                       

_______________
(1) Management uses cash available for dividend as a supplemental performance measure to compute the coverage ratio of estimated cash flows to planned dividends.

Archrock, Inc.

Unaudited Supplemental Information

Reconciliation of Cash Flows From Operating Activities to Free Cash Flow and Free Cash Flow After Dividend

(in thousands)

  Three Months Ended   Year Ended
  December 31,    September 30,    December 31,    December 31,    December 31, 
  2022   2022   2021   2022   2021
Net cash provided by operating activities $ 37,118     $ 76,808     $ 28,675     $ 203,450     $ 237,400  
Net cash used in investing activities   (64,370 )     (20,512 )     (21,747 )     (130,916 )     16,107  
Free cash flow (1)   (27,252 )     56,296       6,928       72,534       253,507  
Dividends paid to stockholders   (22,589 )     (22,559 )     (22,351 )     (90,315 )     (89,343 )
Free cash flow after dividend (1) $ (49,841 )   $ 33,737     $ (15,423 )   $ (17,781 )   $ 164,164  
                                       

_______________
(1) Management believes free cash flow and free cash flow after dividend provide useful information to investors because these non–GAAP measures, when viewed with our GAAP results and accompanying reconciliations, provide a more complete understanding of our performance than GAAP results alone. Management uses these non–GAAP measures as supplemental measures to review current period operating performance, comparability measures and performance measures for period–to–period comparisons.

Archrock, Inc.

Unaudited Supplemental Information

Reconciliation of Net Income to Adjust EBITDA and Cash Available for Dividend

(in thousands)

  Annual Guidance Range
  2023
  Low   High
Net income (1) $ 75,000     $ 105,000  
Interest expense   111,000       111,000  
Provision for income taxes   33,000       33,000  
Depreciation and amortization   167,000       167,000  
Stock-based compensation expense   12,000       12,000  
Amortization of capitalized implementation costs   2,000       2,000  
Adjusted EBITDA (2)   400,000       430,000  
Less: Maintenance capital expenditures   (75,000 )     (80,000 )
Less: Other capital expenditures   (15,000 )     (15,000 )
Less: Cash interest expense   (108,000 )     (108,000 )
Cash available for dividend (3)(4) $ 202,000     $ 227,000  
               

_______________
(1) 2022 annual guidance for net income does not include the impact of long-lived and other asset impairment because due to its nature, it cannot be accurately forecasted. Long-lived and other asset impairment does not impact Adjusted EBITDA or cash available for dividend, however it is a reconciling item between these measures and net income. Long-lived and other asset impairment for both 2021 and 2020 was $21.4 million.
(2) Management believes Adjusted EBITDA provides useful information to investors because this non-GAAP measure, when viewed with our GAAP results and accompanying reconciliations, provides a more complete understanding of our performance than GAAP results alone. Management uses this non-GAAP measure as a supplemental measure to review current period operating performance, comparability measure and performance measure for period-to-period comparisons.
(3) Management uses cash available for dividend as a supplemental performance measure to compute the coverage ratio of estimated cash flows to planned dividends.
(4) A forward-looking estimate of cash provided by operating activities is not provided because certain items necessary to estimate cash provided by operating activities, including changes in assets and liabilities, are not estimable at this time. Changes in assets and liabilities were $(24.5) million and $(9.5) million for 2022 and 2021, respectively.



U.S. Global Investors Receives Expected Nasdaq Notice Regarding Late Filing of Form 10-Q

San Antonio, TX, Feb. 21, 2023 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a registered investment advisory firm with longstanding experience in global markets and specialized sectors, today announces that it received a standard notification letter dated February 16, 2023, (the “Nasdaq notice” or “notice”) from the Nasdaq Listing Qualifications Department of Nasdaq notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5250 (c)(1), which requires timely filing of all required financial reports with the U. S. Securities and Exchange Commission.

The Nasdaq notice has no immediate impact on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. The notice provides that the Company has until April 17, 2023 (that is, 60 calendar days from the date of the Nasdaq notice) to submit to Nasdaq a plan (the “Compliance Plan”), to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the Compliance Plan, Nasdaq can grant the Company an exception to extend for an additional 180 calendar days from the extended due date of the Form 10-Q filing date, or August 14, 2023, to regain compliance. The Company is working diligently to file its Form 10-Q.

This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.

About U.S. Global Investors, Inc.

The story of U.S. Global Investors goes back more than 50 years when it began as an investment club. Today, U.S. Global Investors, Inc. (www.usfunds.com) is a registered investment adviser that focuses on niche markets around the world. Headquartered in San Antonio, Texas, the Company provides investment advisory services to U.S. Global Investors Funds and U.S. Global ETFs.


To sign up for news and research on a variety of asset classes, from gold to airlines to digital assets, please



click here.


Follow U.S. Global


Investors on Twitter by 



clicking here.


Subscribe to U.S. Global Investors’ YouTube channel b






clicking here.

# # #



Holly Schoenfeldt
U.S. Global Investors, Inc.
210.308.1268
[email protected]